Start the conversation
Like many issues, Donald Trump has been all over the map on the legal marijuana question.
Way back in 1990, the president-elect said the United States needed to legalize all drugs and use the tax revenue to educate Americans about the dangers of drugs. (He may have been joking.)
More recently, he's been hesitant on legal recreational marijuana but bullish on the medical kind.
"In terms of marijuana and legalization, I think that should be a state issue, state-by-state," Trump recently told reporters. "Marijuana is such a big thing. I think medical should happen - right? Don't we agree? I think so. And then I really believe we should leave it up to the states."
Whatever Trump's opinion, the overwhelming "Yes" vote on Nov. 8 just unleashed a tsunami of cash.
That tsunami is heading in the direction of marijuana companies - and in the direction of those companies' investors.
Already, one of those medical "pot stocks" is starting to pull ahead of the pack.
That's because it's clear that Trump's position on medical marijuana will boost the fortunes of companies that are working on marijuana-derived pharmaceuticals. Companies just like this one.
And you could boost your own fortune with it.
The One Pharma Stock to Play the Medical Marijuana Market
Study after study has shown that up to two dozen medical conditions could be treated with marijuana.
Its two key ingredients, cannabidiol (CBD) and tetrahydrocannabinol (THC), have a clear impact on brain function and pain management.
Glaucoma sufferers, for example, have long known that pot can reduce ocular swelling. Many people swear by pot's ability to improve lung function, counterintuitive as that may seem. And people suffering from conditions such as multiple sclerosis will tell you that this drug can greatly ease the daily pain they must live with.
Results like those are why voters and legislators have approved medical marijuana across the United States and in many countries around the world - including voters in four states just over a week ago.
The legal market for medical marijuana exceeded $4 billion last year and will likely be a $10 billion industry within a few years, according to ArcView Market Research.
And the company I want to show you now is one of the prime players in this hot sector: GW Pharmaceuticals Plc. (Nasdaq ADR: GWPH).
This UK biotech firm manufactures pain drugs using compounds present in cannabis. GW Pharma has developed a multiple sclerosis treatment and has another drug in the works to treat children with severe epilepsy.
Just a few months ago, GW raised $252 million in funding, with Morgan Stanley, Bank of America Merrill Lynch, and Goldman Sachs serving as underwriters.
GW has a great head start in the race to build drug franchises around the healing powers of cannabis...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.